Breathing dysfunction in Rett syndrome: Understanding epigenetic regulation of the respiratory network

Breathing dysfunction in Rett syndrome: Understanding epigenetic regulation of the respiratory network
Michael Ogier and David M. Katz^*
Department of Neurosciences, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106-4975, United States
^*Corresponding author. Tel.: +1 216 368 6116; fax: +1 216 368 4650. E-mail address: Abstractdavid.katz@case.edu (D.M. Katz)
The publisher's final edited version of this article is available at Respir Physiol Neurobiol.
See other articles in PMC that cite the published article.

• Abstract
• Severely arrhythmic breathing is a hallmark of Rett syndrome (RTT) and profoundly affects quality of life for patients and their families. The last decade has seen the identification of the disease-causing gene, methyl-CpG-binding protein 2 (Mecp2) and the development of mouse models that phenocopy many aspects of the human syndrome, including breathing dysfunction. Recent studies have begun to characterize the breathing phenotype of Mecp2 mutant mice and to define underlying electrophysiological and neurochemical deficits. The picture that is emerging is one of defects in synaptic transmission throughout the brainstem respiratory network associated with abnormal expression in several neurochemical signaling systems, including brain-derived neurotrophic factor (BDNF), biogenic amines and gamma-amino-butyric acid (GABA). Based on such findings, potential therapeutic strategies aimed at improving breathing by targeting deficits in neurochemical signaling are being explored. This review details our current understanding of respiratory dysfunction and underlying mechanisms in RTT with a particular focus on insights gained from mouse models.
  Keywords: Rett Syndrome, Methyl-CpG-binding protein 2, Breathing, Synaptic transmission
  1. Introduction
  Rett syndrome is a severe neurodevelopmental disorder with a prevalence of approximately 1 in 10,000 live female births. Affected children undergo apparently normal postnatal development until 6–18 months of age and then begin a marked neurological decline with a highly variable course that can include an early period of developmental regression followed by phases of symptom stabilization as well as late deterioration (Hagberg et al., 1983; Shahbazian et al., 2002; Vorsanova et al., 2004; Chahrour and Zoghbi, 2007). Initial manifestations of the disease may include loss of acquired speech, head growth deceleration and autistic features such as emotional withdrawal and diminished eye contact. Subsequently, RTT patients develop motor stereotypies, epileptiform seizures, exaggerated responses to stress and autonomic dysfunction. Of particular relevance to this review is that the majority of RTT patients also develop severe breathing abnormalities.
  The vast majority of typical RTT cases are attributable to loss-of-function mutations in the gene encoding methyl-CpG-binding protein 2 (MeCP2; Amir et al., 1999; Shahbazian and Zoghbi, 2001). MeCP2 belongs to a family of methyl-binding proteins (Klose and Bird, 2006) that regulate gene expression by repressing transcription at methylated promoters. Thus, MeCP2 is considered an epigenetic regulator because it is able to influence patterns of gene expression from outside the genome by "reading" methylation patterns in the DNA and repressing target genes.
  The Mecp2 gene is located on the X chromosome and homozygous mutation is invariably lethal. Affected females are heterozygotes and most male infants carrying an Mecp2 mutation die shortly after birth. Female heterozygotes are somatic mosaics for RTT, i.e., cells in which the mutated allele occurs on the inactive X are phenotypically normal, whereas cells in which the mutated allele occurs on the active X are mutant. Thus, it is thought that disease phenotype depends not only on the specific mutation but also on the skewing of X chromosome inactivation, such that individuals in which inactivation is skewed towards the mutant allele are less severely affected, and vice versa. However, recent studies indicate that disease severity cannot always be explained by X inactivation patterns, pointing to a role for other modifiers of Mecp2 gene function (Takahashi et al., 2008; Xinhua et al., 2008).
  There are currently no treatments available for Rett syndrome. Therefore, understanding the molecular pathogenesis of Rett syndrome is important, first and foremost, for developing therapeutic strategies aimed at improving the quality of life for affected individuals. There are likely to be other benefits as well. For example, Mecp2 mutations, as well as gene duplications, have now been identified in other disorders, including some forms of autism (Moretti and Zoghbi, 2006). More broadly, the study of Rett syndrome is shedding light on basic mechanisms of epigenetic regulation and their importance for nervous system development and function.
• 
  
  References
  2. MeCP2 function and target genes
  The MeCP2 protein contains at least 2 functional domains: a methyl-binding domain (MBD) that recognizes methylated CpG dinucleotides with particular flanking sequences (Klose and Bird, 2006), and a transcription repression domain (TRD). Over 200 different Mecp2 mutations have been found in Rett patients, with many clustered in the MBD and TRD sequences.
  The repressor activity of MeCP2 results not only from its intrinsic TRD but also from its ability to recruit complexes comprised of histone deacetylases and other proteins with transcriptional repressor activity (Klose and Bird, 2006). More recently, additional domains have been identified within MeCP2 that bind DNA at non-methylated sites (Nikitina et al., 2007a,b). Thus, it is likely that transcriptional repression at specific gene promoters is not the only function of MeCP2. In particular, increasing evidence supports a role in higher order chromatin structure (Nikitina et al., 2007a) and there are also data to suggest a role in RNA splicing (Young et al., 2005).
  Despite extensive characterization of it's repressor activity in vitro, relatively few bona fide transcriptional targets of MeCP2 have been identified. This is somewhat surprising given that the structure of MeCP2 predicts a widespread role in gene repression. Several laboratories have attempted to identify MeCP2 targets by comparing gene expression profiles in brain samples from wildtype and Mecp2 null mice using RNA microarrays, the prediction being that many genes would be upregulated in mutant animals in the absence of MeCP2. Another approach has been chromatin immunoprecipitation (ChIP), a technique in which DNA-binding proteins are cross-linked to chromatin in intact cells and then immunoprecipated with anti-MeCP2 antibodies. The immunoprecipitated chromatin fragments are then identified by quantitative real-time polymerase chain reaction with oligonucleotide probes directed against specific DNA sequences. Relatively few validated gene targets have yet emerged from either of these approaches (Colantuoni et al., 2001; Johnston et al., 2001; Traynor et al., 2002; Tudor et al., 2002; Ballestar et al., 2003; Nuber et al., 2005; Delgado et al., 2006; Kriaucionis et al., 2006; Peddada et al., 2006; Deng et al., 2007; Jordan et al., 2007; Smrt et al., 2007). One explanation may be that patterns of gene regulation by MeCP2 are highly dependent on cellular context, and that differences in expression between wildtype and null cells are diluted or averaged out when analyzing expression profiles in heterogenous tissues such as whole brain. Moreover, ChIP data have recently been used to propose that MeCP2 actually binds to potentially thousands of genes, including both actively transcribed and repressed genes (Yasui et al., 2007). However, recent studies have questioned whether or not such data actually reveal functional binding and have called into serious question the ability of ChIP to distinguish genuine targets of transcription factors from non-specific DNA-binding sites (Li et al., 2008).
• 3. Mouse models of RTT
  Identification of Mecp2 as the disease-causing gene in human RTT patients stimulated the development of mouse models of RTT in which Mecp2 is either deleted, mutated or overexpressed, including 1) Mecp2^−/y mice with extended exonic deletion of the Mecp2 gene (Chen et al., 2001; Guy et al., 2001; Pelka et al., 2006), 2) Mecp2^308/y mice with truncation of Mecp2 protein at amino acid 308, a human RTT mutation (Shahbazian et al., 2002), 3) Mecp2^Flox/y mice expressing a hypomorphic Mecp2 allele (Samaco et al., 2008) and 4) Mecp2^Tg1 mice that overexpress MeCP2 protein (Collins et al., 2004). As discussed in detail below, the loss-of-function mouse models exhibit varying degrees of RTT-like pathophysiology, including disturbances of breathing, and are therefore proving valuable in defining links between Mecp2 mutations and neurologic dysfunction. As with human RTT patients, homozygous female Mecp2 mutants are not viable and heterozygous females are phenotypically heterogeneous due to variable patterns of X-chromosome inactivation. Therefore, most laboratories have studied the effects of Mecp2 loss of function in hemizygous males (Mecp2^−/y), which are completely null for Mecp2 and therefore tend to be more phenotypically homogenous than female heterozygotes (see however Bissonnette and Knopp, 2006, 2008; Bissonnette et al., 2007).
• 4. RTT symptoms can be reversed in mice
  A conceptual breakthrough in RTT research came in 2007 with the demonstration that RTT symptoms in mice are at least partially reversible. To approach this issue, Guy et al. (2007) created a mouse line in which the endogenous Mecp2 gene is silenced by insertion of a Lox-Stop cassette linked to a modified estrogen receptor. The Mecp2 gene is turned off in these animals until the Lox-Stop cassette is excised by Cre-mediated deletion triggered by exposure to tamoxifen. Using these animals, Guy et al. (2007) demonstrated that reactivation of Mecp2 in severely symptomatic adult "null" mice resulted in significant reversal of their RTT-like phenotype, including marked improvement in lifespan, motor function and grossly observable breathing behavior. Qualitatively similar results were reported by Giacometti et al. (2007) and more recently by Jugloff et al. (2008). These remarkable findings suggest that, in mice, RTT-like symptoms do not result from irreversible changes in brain structure or function and raise the possibility that therapeutic strategies aimed at restoring MeCP2 dependent signaling, even in symptomatic RTT patients, could be clinically beneficial.
• 5. Morphological changes in the RTT brain
  Consistent with the results of genetic reversibility experiments in mice, the brains of RTT patients and Mecp2 null mice do not exhibit gross morphological abnormalities. Despite profound neurological dysfunction, the major morphological change in the central nervous system of animal models and human RTT patients is a reduction in brain size without detectable cell loss (see however Kitt and Wilcox, 1995). Rather, reduction of brain size in RTT is associated with evidence of hypomorphic neuronal traits, including (1) marked reduction in dendritic branching of layer III and V pyramidal neurons in the frontal, temporal and motor cortices, and of layer II and IV neurons in the subiculum (Armstrong, 2005), (2) shortening of dendritic spines in the frontal cortex (Belichenko et al., 1994), (3) reduction in neuronal size in the cortex, thalamus, basal ganglia, amygdala, and hippocampus (Kitt and Wilcox, 1995), and (4) dysmorphic olfactory neurons (Ronnett et al., 2003). Similarly, Mecp2^−/y mice exhibit reduced cortical dendritic arborization (Kishi and Macklis, 2004), delayed neuronal maturation and synaptogenesis in the cerebral cortex (Fukuda et al., 2005) and possible reductions in synapse number in the hippocampus (Chao et al., 2007).
• 6. Electrophysiological perturbations in RTT
  RTT patients exhibit numerous electrophysiological abnormalities suggestive of cortical hyperexcitability, including a higher incidence of epileptiform seizures and appearance of rhythmic slow theta activity (Glaze, 2005). In mouse models, on the other hand, loss of MeCP2 function appears to be associated with an imbalance between excitatory and inhibitory neurotransmission that can favor either excitation or inhibition, depending on the brain region and experimental preparation. For example, spontaneous neuronal activity in adult cortical slices is reduced in Mecp2^−/y mice due to a decrease in total excitatory synaptic drive and an increase in the total inhibitory drive (Dani et al., 2005). Mecp2^−/y mice exhibit a reduction in the number of hippocampal excitatory glutamatergic synapses in vivo (Chao et al., 2007), as well as decreased frequency of spontaneous excitatory synaptic transmission in cell culture (Nelson et al., 2006). Moreover, in single neuron microcultures, Mecp2^−/y hippocampal neurons exhibit a reduction in the number of excitatory autaptic synaptic inputs (Chao et al., 2007). In contrast, Zhang et al. (2008) recently demonstrated that hippocampal slices from Mecp2^−/y mice exhibit a reduction in inhibitory rhythms that apparently renders the slice prone to hyperexcitability. Changes in synaptic plasticity have also been reported, including reduced long term potentiation (LTP) in Mecp2^−/y cortical slices (Asaka et al., 2006) and in Mecp2^308/y cortical and hippocampal slices (Moretti et al., 2006), enhanced LTP in MeCP2-overexpressing Mecp2^Tg1 hippocampal slices (Collins et al., 2004) and an increase in the rate of short-term synaptic depression in cultured hippocampal neurons (Nelson et al., 2006).
  Loss of MeCP2 function is also associated with an excitatory/inhibitory imbalance in the mouse brainstem, including in cell groups involved in regulation of breathing. Stettner et al. (2007) recently described hyperexcitability of neurons located in the medulla oblongata and pons of Mecp2^−/y mice, most probably due to increased excitatory drive. In addition, the amplitude and frequency of spontaneous inhibitory synaptic currents is severely depressed in neurons located in the rostral ventrolateral medulla of Mecp2^−/y mice (Medrihan et al., 2008).
• 7. Breathing disturbances in RTT patients
  Breathing dysfunction in RTT is complex and highly variable, both among affected individuals and within individuals, depending, for example, on the level of behavioral arousal. In general the RTT breathing phenotype is characterized by forced and apneustic breathing, increased occurrence of apneas, and highly unstable breathing patterns including periods of breath-holds, episodes of hyperventilation and heterogeneous breath duration (Weese-Mayer et al., 2006 and references therein). Mean respiratory frequency is increased by approximately 20%. Although originally thought to occur only during wakefulness, some recent studies have observed breathing disturbances during sleep as well (Rohdin et al., 2007). Initial studies aimed at characterizing the pathophysiology of RTT in human patients suggested several possible causes for breathing disturbances, including cortical dysfunction (Elian and Rudolf, 1991; Marcus et al., 1994) and brainstem immaturity (Julu et al., 1997).
• 8. Breathing disturbances in Mecp2 null mice
  Mecp2^−/y male mice develop breathing abnormalities similar to human RTT, however, significant differences in respiratory phenotype exist among different mouse strains. In general, the two strains studied thus far, i.e., Mecp2^tm1.1Bird (Guy et al., 2001) and Mecp2^tm1.1Jae (Chen et al., 2001) both exhibit increased variability in breath duration and episodes of hyperventilation, as determined in vivo using whole-body plethysmography (Viemari et al., 2005; Ogier et al., 2007; Zanella et al., 2008) and in vitro using electro-physiologic assessment of phrenic and vagal nerve activities from working heart-brainstem preparations (Stettner et al., 2007). Male Mecp2^tm1.1Bird null mice breathe normally until approximately one month of age, after which they develop erratic breathing characterized by increased variability in the duration of the respiratory cycle, leading to alternating periods of fast and slow breathing frequencies, and by occurrence of apneas (Viemari et al., 2005). Initial breathing disturbances worsen between the first and second months and the mice eventually die from fatal respiratory arrest. Before dying, Mecp2^tm1.1Bird null mice display a slow and arrhythmic breathing pattern with a highly variable cycle period, decreased mean breathing frequency and an increasing occurrence of long-lasting apneas (Viemari et al., 2005; Roux et al., 2007; Stettner et al., 2007; Zanella et al., 2008). The increased variability of total breath duration has been linked to the duration of post-inspiratory and inspiratory phases (Stettner et al., 2007), and does not depend on altered peripheral chemoreceptor oxygen sensitivity (Bissonnette and Knopp, 2008). Increased respiratory variability and apneas have also been reported in Mecp2^Flox/y hypomorphs, mice that express approximately 50% lower levels of MeCP2 protein in the brain (Samaco et al., 2008). However, unlike RTT patients, no change in the mean breathing frequency has been reported in Mecp2^tm1.1Bird or Mecp2^Flox/y mice.
  Male Mecp2^tm1.1Jae null mice also exhibit severely disordered breathing with alternating periods of high respiratory frequency and normal breathing by 5 weeks of age (Fig. 1; Ogier et al., 2007). Occurrence of apneas shows a high degree of individual variation at this stage. Unlike Mecp2^tm1.1Bird null mice, mean breathing frequency (and minute ventilation) is significantly increased in 5-week-old Mecp2^tm1.1Jae null mice compared to wildtype controls by approximately 20%, similar to human RTT patients (Weese-Mayer et al., 2006). Differences in the breathing phenotypes of Mecp2^tm1.1Jae and Mecp2^tm1.1Bird null mice could result from subtle differences in the exonic deletion between the two strains. However, a more likely explanation is that the two mouse strains have different genetic backgrounds. For example, the fact that C57BL/6 mice are particularly prone to spontaneous apneas from central origin (Stettner et al., 2008a, 2008b) might explain why the apneic phenotype is more pronounced in Mecp2^tm1.1Bird null mice, engineered on a pure C57BL/6 background, compared to Mecp2^tm1.1Jae null mice, engineered on a mixed C57BL/6, 129/sv, Balb/c background.

• Fig. 1 Mecp2tm1.1Jae null mice exhibit a Rett-like respiratory phenotype at 5 weeks of age (P35). Representative plethysmographic recordings of quiet breathing from wildtype and Mecp2tm1.1Jae null mice. In contrast to the wildtype pattern of regular breathing, (more ...)

  Bissonnette and Knopp (2006) have recently suggested that respiratory dysfunction in Mecp2 mutant mice is not only of neurogenic origin but also results from MeCP2 deficiency in peripheral tissues. Using plethysmography, they compared the respiratory phenotype of 5-month-old female Mecp2^tm1.1Bird heterozygotes to age-matched wildtypes and females with neuron-specific mutation of Mecp2 (Mecp2^{+/nestin-Cre-lox}) and reported that the two mutants display distinct respiratory phenotypes. Mecp2^tm1.1Bird heterozygotes breathe slowly compared to wild-types, and have an increased mean tidal volume. In contrast, female Mecp2^{+/nestin-Cre-lox} heterozygotes have a higher mean breathing frequency and a reduced mean tidal volume. In addition, Mecp2^tm1.1Bird heterozygotes exhibit increased duration of apneas in response to hypoxia-induced hyperventilation compared to Mecp2^{+/nestin-Cre-lox} heterozygotes. These observations may indicate that peripheral MeCP2 deficiency can influence breathing, however, further studies are needed to rule out possible influences of strain differences between Mecp2^tm1.1Bird and Mecp2^{+/nestin-Cre-lox} mice as well.
• 9. Respiratory network abnormalities in Mecp2 null mice
  9.1. Neurophysiological defects
  Several recent electrophysiological studies in Mecp2 null mice have begun to reveal specific functional alterations in the brainstem respiratory network that likely contribute to the abnormal breathing phenotype observed in intact animals. Using an in vitro preparation of acute brainstem slices to record bursting activity from the ventral respiratory group, Viemari et al. (2005) described a significant increase in the coefficient of variation and irregularity score for respiratory cycle length in mutant slices compared to age-matched wildtype controls at 2–3 weeks of age. Although consistent with breathing arrhythmia, as in older Mecp2 null mice, these changes preceed detectable differences in respiratory function between wildtype and mutant animals by several weeks. Stettner et al. (2007) recently demonstrated that breathing arrhythmia is associated with impaired control of post-inspiratory activity caused by unpredictable fluctuations in the duration and amplitude of the post-inspiratory vagal afferent discharge, leading in turn to a significant increase in the variability of expiratory cycle length. In addition, they observed a loss of desensitization of the Hering–Breuer reflex in response to repeated vagal afferent stimulation in mutant animals compared to wildtype controls. Moreover, they observed hyperexcitablity of respiratory-related neurons in the pontine Kölliker-Fuse nucleus characterized by exaggerated responses to exogenous glutamate. Together, these data indicate disruptions in two different neural systems that play key roles in modulation of the respiratory rhythm in general and expiratory cycle length in particular, i.e., vagal afferent inputs and the Kölliker-Fuse nucleus. Therefore, Stettner et al. (2007) propose that alterations in the control of post-inspiratory activity contribute to the respiratory phenotype in Mecp2 null mice, and possibly RTT patients, by generating breathing arrhythmias and increasing the incidence of apneas. Moreover, in light of the fact that post-inspiratory motor output plays a key role in regulating laryngeal adductors and, therefore, upper airway patency, these data could help explain upper airway-related problems in RTT, including apneas with laryngeal closure, loss of speech (Budden et al., 1990) and weak coordination of breathing and swallowing (Morton et al., 1997; Isaacs et al., 2003).
  Finally, Medrihan et al. (2008) have recently described very early changes in synaptic function in the ventrolateral medulla of Mecp2 null mice. Specifically, they showed that, as early as one week after birth, the frequency and amplitude of spontaneous inhibitory postsynaptic currents (IPSCs) recorded from the rostal ventrolateral medulla is severely depressed in Mecp2 null mice compared to wildtype controls. Thus, although overt respiratory dysfunction does not become apparent until several weeks after birth (Viemari et al., 2005; Stettner et al., 2007), increasing evidence indicates that network abnormalities begin to appear much sooner.
  9.2. Neurochemical defects in the brainstem respiratory network in Mecp2 null mice
  In an attempt to understand the molecular bases of respiratory network dysfunction in RTT, a number of laboratories have examined expression and function of neurotransmitter systems in the Mecp2 null mouse brainstem. These studies have focused in particular on three signaling systems; brain-derived neurotrophic factor (BDNF), biogenic amines (notably norepinephrine and serotonin) and the inhibitory transmitter gamma-amino butyric acid (GABA), all of which play pivotal roles in the development and/or function of the brainstem respiratory network.
  9.2.1. BDNF
  BDNF plays critical roles in survival, maturation and plasticity of neurons throughout the neuraxis and is essential for development of the respiratory controller and normal breathing behavior (for review see Katz, 2005). In the perinatal period, BDNF is required for survival of peripheral cranial sensory afferents in the nodose and petrosal ganglia, including baroreceptor and chemoafferent neurons, as well as neurons in the pontine A5 noradrenergic cell group (Guo et al., 2005; Huang et al., 2005), an important source of modulatory input to medullary respiratory neurons. Moreover, BDNF is required for perinatal development of central respiratory output (Balkowiec and Katz, 1998) and modulates synaptic function in newborn and adult animals at multiple sites within the respiratory network, including the nucleus tractus solitarius (Balkowiec et al., 2000), preBötzinger complex (Thoby-Brisson et al., 2003), Kölliker-Fuse nucleus (Kron et al., 2007a,b) and spinal phrenic motoneurons (Baker-Herman et al., 2004). The synaptic modulatory role of BDNF derives from the fact that many neurons express BDNF throughout life and release it in an activity-dependent manner (Balkowiec and Katz, 2000, 2002). BDNF null mice die within a few weeks of birth, most likely from breathing complications that include severely depressed minute ventilation, highly variable respiratory cycle length and increased occurrence of apneas (Erickson et al., 1996).
  A possible link between BDNF and RTT was suggested by evidence that the BDNF gene is a transcriptional target of MeCP2 (Chen et al., 2003; Martinowich et al., 2003). Subsequently, studies in this and other laboratories demonstrated that Mecp2 null mice exhibit marked progressive deficits in brain content of BDNF after birth (Wang et al., 2006; Chang et al., 2006). The finding that BDNF gene expression is reduced in Mecp2 null mutants conflicts with the notion that MeCP2 is a transcriptional repressor of BDNF, and mechanisms of BDNF regulation by MeCP2 remain a subject of controversy.
  The earliest and most profound declines in BDNF mRNA and protein in Mecp2 null mice occur in the nodose ganglion and brainstem, including nTS, with mutants exhibiting 40–50% wildtype levels by 5 weeks after birth (Wang et al., 2006). These declines are not due to loss of BDNF expressing neurons, as cell survival is unchanged in mutant mice compared to controls (Wang et al., 2006). The lack of an effect on cell number reflects the fact that BDNF deficits in Mecp2 null mice occur several weeks after birth, at a time when neurons are no longer dependent on BDNF for survival.
  Deficits in BDNF protein are a likely factor contributing to synaptic dysfunction in Mecp2 null mice. Indeed, we have previously shown that BDNF can potently modulate activity of second order relay neurons in nTS by inhibiting postsynaptic glutamatergic AMPA receptors (Balkowiec et al., 2000). We hypothesize that decreased BDNF expression by nodose ganglion cells in Mecp2 null mice, leading to reduced synaptic inhibition at primary afferent synapses in nTS, contributes to the loss of reflex desensitization to repeated vagal stimulation in mutant animals (Stettner et al., 2007). Further work is required to test this hypothesis, as well as the possibility that dysregulation of BDNF expression contributes to synaptic dysfunction in the Kölliker-Fuse nucleus (Kron et al., 2007a,b), preBötzinger complex (Thoby-Brisson et al., 2003) and phrenic motoneurons (Baker-Herman et al., 2004).
  9.2.2. Biogenic amines
  Norepinephrine, dopamine and serotonin levels in the Mecp2 null brain as a whole exhibit significant gradual decline after birth compared to wildtype animals (Ide et al., 2005). This is particularly true in the brainstem, where a postnatal deficit in norepinephrine is associated with a decrease in the number of neurons in the A1/C1 and A2/C2 cell groups expressing the catecholamine-synthesizing enzyme tyrosine hydroxylase (TH; Viemari et al., 2005; Roux et al., 2007) and decreased TH content in the pontine A6 cell group of Mecp2^−/y mice (Ogier et al., 2006). Based on these findings, pre-clinical and clinical studies are currently in progress to examine the efficacy of increasing noradrenergic signaling for improving respiratory function in RTT (see below).
  9.2.3. GABAergic signaling
  As noted above, Medrihan et al. (2008) recently demonstrated reduced inhibitory synaptic inputs to rostral ventrolateral medullary neurons in Mecp2 null mice. They further showed that reduced inhibitory synaptic transmission was due to a specific decrease in IPSCs mediated by GABA, with no change in glycinergic signaling. Furthermore, loss of GABAergic transmission was associated with decreased expression of both pre- and post-synaptic markers of GABA function, including presynaptic levels of GABA and the vesicular inhibitory amino acid transporter, as well as reduced levels of the GABA_A receptor α2 subunit mRNA and protein.
  9.3. Neurochemical alterations in RTT patients
  Numerous studies in RTT patients have attempted to identify neurochemical markers of disease (Wenk, 1997; Blue et al., 1999a,b; Lipani et al., 2000; Armstrong, 2001; Calamandrei et al., 2001; Saito et al., 2001; Riikonen, 2003; Guideri et al., 2004a,b; Paterson et al., 2005). However, many of the findings that have been reported thus far have not been consistent across studies. In addition, some analyses included very small numbers of samples across a broad spectrum of ages, sometimes without adequate normal controls. Nonetheless, some of the human data are consistent with findings of neurochemical alterations in Mecp2 null mice discussed above.
  The possibility that monoaminergic transmission is decreased in RTT patients has been a subject of debate for more than 20 years. Initial studies reported that levels of norepinephrine, serotonin and their respective metabolites are severely decreased in postmortem brain tissues from patients with RTT (Riederer et al., 1985; Brucke et al., 1987; Lekman et al., 1989), with a tendency for more severe phenotypes in older patients (Lekman et al., 1989). These results were corroborated by analysis of cerebrospinal fluid samples from RTT patients (Zoghbi et al., 1985, 1989). However, other investigators failed to demonstrate deficits in serotonin and norepinephrine metabolites in cerebrospinal fluid of RTT patients (Perry et al., 1988; Lekman et al., 1990). More recently, a reduction in the level of tyrosine hydroxylase, the rate-limiting enzyme in catecholamine biosynthesis, was observed in the locus coeruleus region in the brain of one patient with RTT, suggesting hypoactivity of brain norepinephrinergic transmission (Saito et al., 2001). However, this observation has not yet been corroborated and more such studies are needed. As discussed above, Mecp2 null mice exhibit significant decreases in brainstem levels of norepinephrine and serotonin and these changes, in norepinephrine in particular, are thought to play an important role respiratory dysfunction (Viemari et al., 2005). Thus, it is critical, particularly given current efforts to develop RTT therapies that target noradrenergic signaling (see below), that the presence or absence of abnormalities in catecholamine metabolism in RTT patients be resolved.
  Glutamate is reported to be elevated in the cerebrospinal fluid (Hamberger et al., 1992; Lappalainen and Riikonen, 1996) and postmortem brain samples (Pan et al., 1999) from RTT patients. Substance P, on the other hand, is decreased in the cerebrospinal fluid (Matsuishi et al., 1997), and in the dorsal horn and intermediolateral column of the spinal cord, spinal trigeminal tract, solitary tract and nucleus, parvocellular and pontine reticular nuclei, the parabrachial complex and locus coeruleus, and, to a lesser extent in the substantia nigra, central gray of the midbrain, frontal cortex, caudate, putamen, globus pallidus and thalamus (Deguchi et al., 2000; Saito et al., 2001). Given the pivotal roles played by glutamate and substance P in regulation of respiratory function (Hilaire and Duron, 1999; Ramirez and Viemari, 2005), these findings, while still quite general, may be relevant to respiratory disturbances in RTT.
• 10. Potential therapeutic targets for treatment of breathing dysfunction in RTT: preclinical studies in mice
  The mortality rate among RTT patients is significantly increased (up to 13 times) compared to the general population, and up to 26% of RTT patients may die suddenly due to cadiorespiratory failure (Kerr et al., 1997; Kerr and Burford, 2001). However, there are currently no treatments available for respiratory dysfunction in RTT. Therefore, a number of laboratories are actively working on preclinical development of potential therapies based on insights gained from mouse models of RTT.
  10.1. BDNF
  Several lines of evidence suggest that strategies aimed at enhancing BDNF signaling could be of therapeutic benefit in RTT. For example, genetic overexpression of BDNF in Mecp2^tm1-1Jae null mice results in improved somatomotor function and increased lifespan (Chang et al., 2006). More recently, our laboratory has begun exploring the possibility that pharmacologic elevation of endogenous BDNF expression with ampakine drugs could improve respiratory function in Mecp2^tm1-1Jae null mice. Ampakines are benzamide derivatives that acutely facilitate the activity of glutamatergic AMPA receptors (Arai and Kessler, 2007). However, repeated treatment with ampakines increases expression of BDNF mRNA and protein in the forebrain of mice and rats for several days (Lauterborn et al., 2000, 2003; Rex et al., 2006) and augments BDNF dependent synaptic plasticity (Ingvar et al., 1997; Porrino et al., 2005; Rex et al., 2006; Wezenberg et al., 2007). These effects far outlast the very short half-life of ampakine drugs, which is on the order of a few hours, as well as the acute effects on AMPA receptor currents. Based on this long-term action on BDNF expression, ampakine drugs are thought to have potential therapeutic value for treatment of diseases characterized by impaired BDNF function. Recently, our laboratory demonstrated that treatment of Mecp2^tm1-1Jae null mice with one ampakine, CX546, for 3 days restores normal respiratory frequency and minute ventilation (Fig. 2A; Ogier et al., 2007). These behavioral effects were accompanied by a significant increase in expression of BDNF protein in vagal afferent neurons in the nodose ganglion (Fig. 2B). Further work is needed to establish whether or not respiratory improvement following ampakine treatment is a direct result of enhanced BDNF expression. Nonetheless, these data are consistent with the hypothesis that decreased BDNF levels contribute to the respiratory phenotype of Mecp2 null mice and that BDNF may be a druggable target for improving respiratory function in RTT.

• Fig. 2 Chronic treatment with CX546 restores normal breathing frequency and increases BDNF levels in the nodose ganglia in P35 Mecp2tm1.1Jae null mice. (A) Mean respiratory frequency is higher in vehicle-treated Mecp2 null (−/y) mice compared to wildtype (more ...)

  10.2. Noradrenergic signaling
  Based on the finding that brainstem levels of norepinephrine are decreased in Mecp2 null mice, and that exogenous norepinephrine can normalize rhythmic respiratory bursts in Mecp2 null brainstem slices, Viemari et al. (2005) proposed that deficits in brainstem noradrenergic signaling play a key role in the development of respiratory dysfunction in these animals. Based on these observations, Roux et al. (2007) and Zanella et al. (2008) explored the possibility that increasing noradrenergic signaling in vivo with desipramine, a tricyclic antidepressant that inhibits the reuptake of norepinephrine, could improve respiratory function in Mecp2^tm1.1Bird null mice. Either repeated intraperitoneal injection (Roux et al., 2007) or oral administration (Zanella et al., 2008) of desipramine significantly reduced the incidence of apneas and extended lifespan in mutant mice. Further work is required to understand the mechanism of these effects, particularly given that desipramine affects multiple signaling mechanisms in addition to norepinephrine reuptake, including, for example, expression of BDNF (Nibuya et al., 1995). It would be interesting if the efficacy of desipramine in improving respiratory function in Mecp2 null mice is related both to its action as an inhibitor of norepinephrine uptake and by increasing levels of BDNF. Currently, a Phase II clinical trial of desipramine in Rett patients is underway in France (Villard et al., 2007).
• 11. Conclusions
  Studies on the pathogenesis of breathing dysfunction in RTT are still at an early stage. It is clear from mouse models that loss of MeCP2 function profoundly affects the functional integrity of the brainstem respiratory network. However, whether or not these changes result from direct or indirect effects of loss of MeCP2 function is unknown. For example, no direct link has yet been made between dysregulation of a bona fide MeCP2 target and a specific deficit in respiratory behavior. Understanding the molecular pathogenesis of respiratory dysfunction is complicated by the fact that MeCP2 likely regulates multiple target genes, each of which may influence numerous downstream signaling pathways and diverse neuronal subtypes. Thus, it is not surprising that the respiratory phenotype of RTT patients and Mecp2 null mice is complex, and that numerous neurochemical and electrophysiological abnormalities have been described thus far. In general, the picture that is emerging is that genetic loss of MeCP2 has significant effects on synaptic transmission in several brain regions important for respiratory control, including the ventrolateral medulla, the Kölliker-Fuse nucleus in the pons, and the nucleus tractus solitarius. Mechanisms that appear to underlie these transmission defects include reduced levels of biogenic amines, including norepinephrine and serotonin, reduced GABAergic signaling and marked deficits in BDNF expression. However, much more work is needed to fully understand the complex chain of events leading from loss of MeCP2-mediated gene regulation to respiratory dysfunction in RTT. For example, the observation that breathing disturbances in RTT are strongly influenced by the level of behavioral arousal (Kerr, 1992; Marcus et al., 1994; Woodyatt and Murdoch, 1996; Weese-Mayer et al., 2006) suggests that interactions between the brainstem and forebrain (and vice versa) that mediate state-dependent regulation of respiration merit further investigation in mouse models of the disease. The fact that at least some RTT-like symptoms in Mecp2 null mice are reversible (Guy et al., 2007) raises hope that efforts to apply our growing understanding of neurochemical and synaptic defects in mouse models of RTT to preclinical trials will lead to the development of new therapies for RTT patients.
  Acknowledgments
  Dr. Katz's lab is supported by grants from the National Institutes of Health, International Rett Syndrome Foundation and Cortex Pharmaceuticals, Inc. We thank Batool Akhtar-Zaidi for her help with the manuscript.
• References

1. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23:185–188. [PubMed]
2. Arai AC, Kessler M. Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets. 2007;8:583–602. [PubMed]
3. Armstrong DD. Rett syndrome neuropathology review 2000. Brain Dev. 2001;23(Suppl 1):S72–76. [PubMed]
4. Armstrong DD. Neuropathology of Rett syndrome. J Child Neurol. 2005;20:747–753. [PubMed]
5. Asaka Y, Jugloff DG, Zhang L, Eubanks JH, Fitzsimonds RM. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome. Neurobiol Dis. 2006;21:217–227. [PubMed]
6. Baker-Herman TL, Fuller DD, Bavis RW, Zabka AG, Golder FJ, Doperalski NJ, Johnson RA, Watters JJ, Mitchell GS. BDNF is necessary and sufficient for spinal respiratory plasticity following intermittent hypoxia. Nat Neurosci. 2004;7:48–55. [PubMed]
7. Balkowiec A, Katz DM. Brain-derived neurotrophic factor is required for normal development of the central respiratory rhythm in mice. J Physiol. 1998;510(Pt 2):527–533. [PubMed]
8. Balkowiec A, Katz DM. Activity-dependent release of endogenous brain-derived neurotrophic factor from primary sensory neurons detected by ELISA in situ. J Neurosci. 2000;20:7417–7423. [PubMed]
9. Balkowiec A, Katz DM. Cellular mechanisms regulating activity-dependent release of native brain-derived neurotrophic factor from hippocampal neurons. J Neurosci. 2002;22:10399–10407. [PubMed]
10. Balkowiec A, Kunze DL, Katz DM. Brain-derived neurotrophic factor acutely inhibits AMPA-mediated currents in developing sensory relay neurons. J Neurosci. 2000;20:1904–1911. [PubMed]
11. Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J, Cigudosa JC, Huang TH, Esteller M. Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J. 2003;22:6335–6345. [PubMed]
12. Belichenko PV, Oldfors A, Hagberg B, Dahlstrom A. Rett syndrome: 3D confocal microscopy of cortical pyramidal dendrites and afferents. Neuroreport. 1994;5:1509–1513. [PubMed]
13. Bissonnette JM, Knopp SJ. Separate respiratory phenotypes in methyl-CpG-binding protein 2 (Mecp2) deficient mice. Pediatr Res. 2006;59:513–518. [PubMed]
14. Bissonnette JM, Knopp SJ. Effect of inspired oxygen on periodic breathing in methy-CpG-binding protein 2 (Mecp2) deficient mice. J Appl Physiol. 2008;104:198–204. [PubMed]
15. Bissonnette JM, Knopp SJ, Maylie J, Thong T. Autonomic cardiovascular control in methyl-CpG-binding protein 2 (Mecp2) deficient mice. Auto Neurosci. 2007;136:82–89.
16. Blue ME, Naidu S, Johnston MV. Altered development of glutamate and GABA receptors in the basal ganglia of girls with Rett syndrome. Exp Neurol. 1999a;156:345–352. [PubMed]
17. Blue ME, Naidu S, Johnston MV. Development of amino acid receptors in frontal cortex from girls with Rett syndrome. Ann Neurol. 1999b;45:541–545. [PubMed]
18. Brucke T, Sofic E, Killian W, Rett A, Riederer P. Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett-syndrome: a postmortem brain study. J Neural Transm. 1987;68:315–324. [PubMed]
19. Budden S, Meek M, Henighan C. Communication and oral-motor function in Rett syndrome. Dev Med Child Neurol. 1990;32:51–55. [PubMed]
20. Calamandrei G, Aloe L, Hajek J, Zappella M. Developmental profile of serum nerve growth factor levels in Rett complex. Ann Ist Super Sanita. 2001;37:601–605. [PubMed]
21. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron. 2007;56:422–437. [PubMed]
22. Chang Q, Khare G, Dani V, Nelson S, Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron. 2006;49:341–348. [PubMed]
23. Chao HT, Zoghbi HY, Rosenmund C. MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron. 2007;56:58–65. [PubMed]
24. Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet. 2001;27:327–331. [PubMed]
25. Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, Jaenisch R, Greenberg ME. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science. 2003;302:885–889. [PubMed]
26. Colantuoni C, Jeon OH, Hyder K, Chenchik A, Khimani AH, Narayanan V, Hoffman EP, Kaufmann WE, Naidu S, Pevsner J. Gene expression profiling in postmortem Rett syndrome brain: differential gene expression and patient classification. Neurobiol Dis. 2001;8:847–865. [PubMed]
27. Collins AL, Levenson JM, Vilaythong AP, Richman R, Armstrong DL, Noebels JL, David Sweatt J, Zoghbi HY. Mild overexpression of MeCP2 causes a progressive neurological disorder in mice. Hum Mol Genet. 2004;13:2679–2689. [PubMed]
28. Dani VS, Chang Q, Maffei A, Turrigiano GG, Jaenisch R, Nelson SB. Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc Natl Acad Sci USA. 2005;102:12560–12565. [PubMed]
29. Deguchi K, Antalffy BA, Twohill LJ, Chakraborty S, Glaze DG, Armstrong DD. Substance P immunoreactivity in Rett syndrome. Pediatr Neurol. 2000;22:259–266. [PubMed]
30. Delgado IJ, Kim DS, Thatcher KN, LaSalle JM, Van den Veyver IB. Expression profiling of clonal lymphocyte cell cultures from Rett syndrome patients. BMC Med Genet. 2006;7:61. [PubMed]
31. Deng V, Matagne V, Banine F, Frerking M, Ohliger P, Budden S, Pevsner J, Dissen GA, Sherman LS, Ojeda SR. FXYD1 is an MeCP2 target gene overexpressed in the brains of Rett syndrome patients and Mecp2-null mice. Hum Mol Genet. 2007;16:640–650. [PubMed]
32. Elian M, Rudolf ND. EEG and respiration in Rett syndrome. Acta Neurol Scand. 1991;83:123–128. [PubMed]
33. Erickson JT, Conover JC, Borday V, Champagnat J, Barbacid M, Yancopoulos G, Katz DM. Mice lacking brain-derived neurotrophic factor exhibit visceral sensory neuron losses distinct from mice lacking NT4 and display a severe developmental deficit in control of breathing. J Neurosci. 1996;16:5361–5371. [PubMed]
34. Fukuda T, Yamashita Y, Nagamitsu S, Miyamoto K, Jin JJ, Ohmori I, Ohtsuka Y, Kuwajima K, Endo S, Iwai T, Yamagata H, Tabara Y, Miki T, Matsuishi T, Kondo I. Methyl-CpG binding protein 2 gene (MECP2) variations in Japanese patients with Rett syndrome: pathological mutations and polymorphisms. Brain Dev. 2005;27:211–217. [PubMed]
35. Giacometti E, Luikenhuis S, Beard C, Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. Proc Natl Acad Sci USA. 2007;104:1931–1936. [PubMed]
36. Glaze DG. Neurophysiology of Rett syndrome. J Child Neurol. 2005;20:740–746. [PubMed]
37. Guideri F, Acampa M, Blardi P, de Lalla A, Zappella M, Hayek Y. Cardiac dysautonomia and serotonin plasma levels in Rett syndrome. Neuropediatrics. 2004a;35:36–38. [PubMed]
38. Guideri F, Acampa M, Calamandrei G, Aloe L, Zappella M, Hayek Y. Nerve growth factor plasma levels and ventricular repolarization in Rett syndrome. Pediatr Cardiol. 2004b;25:394–396. [PubMed]
39. Guo H, Hellard DT, Huang L, Katz DM. Development of pontine noradrenergic A5 neurons requires brain-derived neurotrophic factor. Eur J Neurosci. 2005;21:2019–2023. [PubMed]
40. Guy J, Hendrich B, Holmes M, Martin JE, Bird A. A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome. Nat Genet. 2001;27:322–326. [PubMed]
41. Guy J, Gan J, Selfridge J, Cobb S, Bird A. Reversal of neurological defects in a mouse model of Rett syndrome. Science. 2007;315:1143–1147. [PubMed]
42. Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol. 1983;14:471–479. [PubMed]
43. Hamberger A, Gillberg C, Palm A, Hagberg B. Elevated CSF glutamate in Rett syndrome. Neuropediatrics. 1992;23:212–213. [PubMed]
44. Hilaire G, Duron B. Maturation of the mammalian respiratory system. Physiol Rev. 1999;79:325–360. [PubMed]
45. Huang L, Guo H, Hellard DT, Katz DM. Glial cell line-derived neurotrophic factor (GDNF) is required for differentiation of pontine noradrenergic neurons and patterning of central respiratory output. Neuroscience. 2005;130:95–105. [PubMed]
46. Ide S, Itoh M, Goto Y. Defect in normal developmental increase of the brain biogenic amine concentrations in the mecp2-null mouse. Neurosci Lett. 2005;386:14–17. [PubMed]
47. Ingvar M, Ambros-Ingerson J, Davis M, Granger R, Kessler M, Rogers GA, Schehr RS, Lynch G. Enhancement by an ampakine of memory encoding in humans. Exp Neurol. 1997;146:553–559. [PubMed]
48. Isaacs JS, Murdock M, Lane J, Percy AK. Eating difficulties in girls with Rett syndrome compared with other developmental disabilities. J Am Diet Assoc. 2003;103:224–230. [PubMed]
49. Johnston MV, Jeon OH, Pevsner J, Blue ME, Naidu S. Neurobiology of Rett syndrome: a genetic disorder of synapse development. Brain Dev. 2001;23(Suppl 1):S206–S213. [PubMed]
50. Jordan C, Li HH, Kwan HC, Francke U. Cerebellar gene expression profiles of mouse models for Rett syndrome reveal novel MeCP2 targets. BMC Med Genet. 2007;8:36. [PubMed]
51. Jugloff DG, Vandamme K, Logan R, Visanji NP, Brotchie JM, Eubanks JH. Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice. Hum Mol Genet. 2008;17:1386–1396. [PubMed]
52. Julu PO, Kerr AM, Hansen S, Apartopoulos F, Jamal GA. Functional evidence of brain stem immaturity in Rett syndrome. Eur Child Adolesc Psychiatry. 1997;6(Suppl 1):47–54. [PubMed]
53. Katz DM. Regulation of respiratory neuron development by neurotrophic and transcriptional signaling mechanisms. Respir Physiol Neurobiol. 2005;149:99–109. [PubMed]
54. Kerr AM. A review of the respiratory disorder in the Rett syndrome. Brain Dev. 1992;14(Suppl):43–45.
55. Kerr AM, Burford B. Towards a full life with Rett disorder. Pediatr Rehabil. 2001;4:157–168. [PubMed]
56. Kerr AM, Armstrong DD, Prescott RJ, Doyle D, Kearney DL. Rett syndrome: analysis of deaths in the British survey. Eur Child Adolesc Psychiatry. 1997;6(Suppl 1):71–74. [PubMed]
57. Kishi N, Macklis JD. MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci. 2004;27:306–321. [PubMed]
58. Kitt CA, Wilcox BJ. Preliminary evidence for neurodegenerative changes in the substantia nigra of Rett syndrome. Neuropediatrics. 1995;26:114–118. [PubMed]
59. Klose RJ, Bird AP. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci. 2006;31:89–97. [PubMed]
60. Kriaucionis S, Paterson A, Curtis J, Guy J, Macleod N, Bird A. Gene expression analysis exposes mitochondrial abnormalities in a mouse model of Rett syndrome. Mol Cell Biol. 2006;26:5033–5042. [PubMed]
61. Kron M, Morschel M, Reuter J, Zhang W, Dutschmann M. Developmental changes in brain-derived neurotrophic factor-mediated modulations of synaptic activities in the pontine Kolliker-Fuse nucleus of the rat. J Physiol. 2007a;583:315–327. [PubMed]
62. Kron M, Zhang W, Dutschmann M. Developmental changes in the BDNF-induced modulation of inhibitory synaptic transmission in the Kolliker-Fuse nucleus of rat. Eur J Neurosci. 2007b;26:3449–3457. [PubMed]
63. Lappalainen R, Riikonen RS. High levels of cerebrospinal fluid glutamate in Rett syndrome. Pediatr Neurol. 1996;15:213–216. [PubMed]
64. Lauterborn JC, Lynch G, Vanderklish P, Arai A, Gall CM. Positive modulation of AMPA receptors increases neurotrophin expression by hippocampal and cortical neurons. J Neurosci. 2000;20:8–21. [PubMed]
65. Lauterborn JC, Truong GS, Baudry M, Bi X, Lynch G, Gall CM. Chronic elevation of brain-derived neurotrophic factor by ampakines. J Pharmacol Exp Ther. 2003;307:297–305. [PubMed]
66. Lekman A, Witt-Engerstrom I, Gottfries J, Hagberg BA, Percy AK, Svennerholm L. Rett syndrome: biogenic amines and metabolites in postmortem brain. Pediatr Neurol. 1989;5:357–362. [PubMed]
67. Lekman A, Witt-Engerstrom I, Holmberg B, Percy A, Svennerholm L, Hagberg B. CSF and urine biogenic amine metabolites in Rett syndrome. Clin Genet. 1990;37:173–178. [PubMed]
68. Li XY, Macarthur S, Bourgon R, Nix D, Pollard DA, Iyer VN, Hechmer A, Simirenko L, Stapleton M, Hendriks CL, Chu HC, Ogawa N, Inwood W, Sementchenko V, Beaton A, Weiszmann R, Celniker SE, Knowles DW, Gingeras T, Speed TP, Eisen MB, Biggin MD. Transcription factors bind thousands of active and inactive regions in the Drosophila blastoderm. PLoS Biol. 2008;6:e27. [PubMed]
69. Lipani JD, Bhattacharjee MB, Corey DM, Lee DA. Reduced nerve growth factor in Rett syndrome postmortem brain tissue. J Neuropathol Exp Neurol. 2000;59:889–895. [PubMed]
70. Marcus CL, Carroll JL, McColley SA, Loughlin GM, Curtis S, Pyzik P, Naidu S. Polysomnographic characteristics of patients with Rett syndrome. J Pediatr. 1994;125:218–224. [PubMed]
71. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, Fan G, Sun YE. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science. 2003;302:890–893. [PubMed]
72. Matsuishi T, Nagamitsu S, Yamashita Y, Murakami Y, Kimura A, Sakai T, Shoji H, Kato H, Percy AK. Decreased cerebrospinal fluid levels of substance P in patients with Rett syndrome. Ann Neurol. 1997;42:978–981. [PubMed]
73. Medrihan L, Tantalaki E, Aramuni G, Sargsyan V, Dudanova I, Missler M, Zhang W. Early defects of GABAergic synapses in the brain stem of a MeCP2 mouse model of Rett syndrome. J Neurophysiol. 2008;99:112–121. [PubMed]
74. Moretti P, Zoghbi HY. MeCP2 dysfunction in Rett syndrome and related disorders. Curr Opin Genet Dev. 2006;16:276–281. [PubMed]
75. Moretti P, Levenson JM, Battaglia F, Atkinson R, Teague R, Antalffy B, Armstrong D, Arancio O, Sweatt JD, Zoghbi HY. Learning and memory and synaptic plasticity are impaired in a mouse model of Rett syndrome. J Neurosci. 2006;26:319–327. [PubMed]
76. Morton RE, Bonas R, Minford J, Tarrant SC, Ellis RE. Respiration patterns during feeding in Rett syndrome. Dev Med Child Neurol. 1997;39:607–613. [PubMed]
77. Nelson ED, Kavalali ET, Monteggia LM. MeCP2-dependent transcriptional repression regulates excitatory neurotransmission. Curr Biol. 2006;16:710–716. [PubMed]
78. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995;15:7539–7547. [PubMed]
79. Nikitina T, Ghosh RP, Horowitz-Scherer RA, Hansen JC, Grigoryev SA, Woodcock CL. MeCP2-chromatin interactions include the formation of chromatosome-like structures and are altered in mutations causing Rett syndrome. J Biol Chem. 2007a;282:28237–28245. [PubMed]
80. Nikitina T, Shi X, Ghosh RP, Horowitz-Scherer RA, Hansen JC, Woodcock CL. Multiple modes of interaction between the methylated DNA binding protein MeCP2 and chromatin. Mol Cell Biol. 2007b;27:864–877. [PubMed]
81. Nuber UA, Kriaucionis S, Roloff TC, Guy J, Selfridge J, Steinhoff C, Schulz R, Lipkowitz B, Ropers HH, Holmes MC, Bird A. Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome. Hum Mol Genet. 2005;14:2247–2256. [PubMed]
82. Ogier M, Wang H, Hellard D, Wang Q, Katz DM. Brain-derived neurotrophic factor (BDNF) and respiratory dysfunction in a mouse model of Rett syndrome. Society for Neuroscience. 2006;3 (Abstract 692).
83. Ogier M, Wang H, Hong E, Wang Q, Greenberg ME, Katz DM. Brain-derived neurotrophic factor expression and respiratory function improve after ampakine treatment in a mouse model of Rett syndrome. J Neurosci. 2007;27:10912–10917. [PubMed]
84. Pan JW, Lane JB, Hetherington H, Percy AK. Rett syndrome: ¹H spectroscopic imaging at 4.1 T. J Child Neurol. 1999;14:524–528. [PubMed]
85. Paterson DS, Thompson EG, Belliveau RA, Antalffy BA, Trachtenberg FL, Armstrong DD, Kinney HC. Serotonin transporter abnormality in the dorsal motor nucleus of the vagus in Rett syndrome: potential implications for clinical autonomic dysfunction. J Neuropathol Exp Neurol. 2005;64:1018–1027. [PubMed]
86. Peddada S, Yasui DH, LaSalle JM. Inhibitors of differentiation (ID1, ID2, ID3 and ID4) genes are neuronal targets of MeCP2 that are elevated in Rett syndrome. Hum Mol Genet. 2006;15:2003–2014. [PubMed]
87. Pelka GJ, Watson CM, Radziewic T, Hayward M, Lahooti H, Christodoulou J, Tam PP. Mecp2 deficiency is associated with learning and cognitive deficits and altered gene activity in the hippocampal region of mice. Brain. 2006;129:887–898. [PubMed]
88. Perry TL, Dunn HG, Ho HH, Crichton JU. Cerebrospinal fluid values for monoamine metabolites, gamma-aminobutyric acid, and other amino compounds in Rett syndrome. J Pediatr. 1988;112:234–238. [PubMed]
89. Porrino LJ, Daunais JB, Rogers GA, Hampson RE, Deadwyler SA. Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates. PLoS Biol. 2005;3:e299. [PubMed]
90. Ramirez JM, Viemari JC. Determinants of inspiratory activity. Respir Physiol Neurobiol. 2005;147:145–157. [PubMed]
91. Rex CS, Lauterborn JC, Lin CY, Kramar EA, Rogers GA, Gall CM, Lynch G. Restoration of long-term potentiation in middle-aged hippocampus after induction of brain-derived neurotrophic factor. J Neurophysiol. 2006;96:677–685. [PubMed]
92. Riederer P, Brucke T, Sofic E, Kienzl E, Schnecker K, Schay V, Kruzik P, Killian W, Rett A. Neurochemical aspects of the Rett syndrome. Brain Dev. 1985;7:351–360. [PubMed]
93. Riikonen R. Neurotrophic factors in the pathogenesis of Rett syndrome. J Child Neurol. 2003;18:693–697. [PubMed]
94. Rohdin M, Fernell E, Eriksson M, Albage M, Lagercrantz H, Katz-Salamon M. Disturbances in cardiorespiratory function during day and night in Rett syndrome. Pediatr Neurol. 2007;37:338–344. [PubMed]
95. Ronnett GV, Leopold D, Cai X, Hoffbuhr KC, Moses L, Hoffman EP, Naidu S. Olfactory biopsies demonstrate a defect in neuronal development in Rett's syndrome. Ann Neurol. 2003;54:206–218. [PubMed]
96. Roux JC, Dura E, Moncla A, Mancini J, Villard L. Treatment with desipramine improves breathing and survival in a mouse model for Rett syndrome. Eur J Neurosci. 2007;25:1915–1922. [PubMed]
97. Saito Y, Ito M, Ozawa Y, Matsuishi T, Hamano K, Takashima S. Reduced expression of neuropeptides can be related to respiratory disturbances in Rett syndrome. Brain Dev. 2001;23(Suppl 1):S122–S126. [PubMed]
98. Samaco RC, Fryer JD, Ren J, Fyffe S, Chao HT, Sun Y, Greer JJ, Zoghbi HY, Neul JL. A partial loss of function allele of methyl-CpG-binding protein predicts a human neurodevelopmental syndrome. Hum Mol Genet. 2008 epub ahead of print.
99. Shahbazian MD, Zoghbi HY. Molecular genetics of Rett syndrome and clinical spectrum of MECP2 mutations. Curr Opin Neurol. 2001;14:171–176. [PubMed]
100. Shahbazian M, Young J, Yuva-Paylor L, Spencer C, Antalffy B, Noebels J, Armstrong D, Paylor R, Zoghbi H. Mice with truncated MeCP2 recapitulate many Rett syndrome features and display hyperacetylation of histone H3. Neuron. 2002;35:243–254. [PubMed]
101. Smrt RD, Eaves-Egenes J, Barkho BZ, Santistevan NJ, Zhao C, Aimone JB, Gage FH, Zhao X. Mecp2 deficiency leads to delayed maturation and altered gene expression in hippocampal neurons. Neurobiol Dis. 2007;27:77–89. [PubMed]
102. Stettner GM, Huppke P, Brendel C, Richter DW, Gartner J, Dutschmann M. Breathing dysfunctions associated with impaired control of postinspiratory activity in Mecp2^−/y knockout mice. J Physiol. 2007;579:863–876. [PubMed]
103. Stettner GM, Zanella S, Hilaire G, Dutschmann M. 8-OH-DPAT suppresses spontaneous central apneas in the C57BL/6J mouse strain. Respir Physiol Neurobiol. 2008b;161:10–15. [PubMed]
104. Stettner GM, Zanella S, Huppke P, Gartner J, Hilaire G, Dutschmann M. Spontaneous central apneas occur in the C57BL/6J mouse strain. Respir Physiol Neurobiol. 2008a;160:21–27. [PubMed]
105. Takahashi S, Ohinata J, Makita Y, Suzuki N, Araki A, Sasaki A, Murono K, Tanaka H, Fujieda K. Skewed X chromosome inactivation failed to explain the normal phenotype of a carrier female with MECP2 mutation resulting in Rett syndrome. Clin Genet. 2008;73:257–261. [PubMed]
106. Thoby-Brisson M, Cauli B, Champagnat J, Fortin G, Katz DM. Expression of functional tyrosine kinase B receptors by rhythmically active respiratory neurons in the pre-Botzinger complex of neonatal mice. J Neurosci. 2003;23:7685–7689. [PubMed]
107. Traynor J, Agarwal P, Lazzeroni L, Francke U. Gene expression patterns vary in clonal cell cultures from Rett syndrome females with eight different MECP2 mutations. BMC Med Genet. 2002;3:12. [PubMed]
108. Tudor M, Akbarian S, Chen RZ, Jaenisch R. Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc Natl Acad Sci USA. 2002;99:15536–15541. [PubMed]
109. Viemari JC, Roux JC, Tryba AK, Saywell V, Burnet H, Pena F, Zanella S, Bevengut M, Barthelemy-Requin M, Herzing LB, Moncla A, Mancini J, Ramirez JM, Villard L, Hilaire G. Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice. J Neurosci. 2005;25:11521–11530. [PubMed]
110. Villard L, Dura E, Mancini J, Moncla A, Roux JC. The American Society of Human Genetics. 2007. Bioaminergic deficits in Rett syndrome: from pathophysiology to clinical trials; p. 2266. Abstract.
111. Vorsanova SG, Iourov IY, Yurov YB. Neurological, genetic and epigenetic features of Rett syndrome. J Pediatr Neurol. 2004;2:179–190.
112. Wang H, Chan SA, Ogier M, Hellard D, Wang Q, Smith C, Katz DM. Dysregulation of brain-derived neurotrophic factor expression and neurosecretory function in Mecp2 null mice. J Neurosci. 2006;26:10911–10915. [PubMed]
113. Weese-Mayer DE, Lieske SP, Boothby CM, Kenny AS, Bennett HL, Silvestri JM, Ramirez JM. Autonomic nervous system dysregulation: breathing and heart rate perturbation during wakefulness in young girls with Rett syndrome. Pediatr Res. 2006;60:443–449. [PubMed]
114. Wenk GL. Rett syndrome: neurobiological changes underlying specific symptoms. Prog Neurobiol. 1997;51:383–391. [PubMed]
115. Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology. 2007;32:1272–1283. [PubMed]
116. Woodyatt GC, Murdoch BE. The effect of the presentation of visual and auditory stimuli on the breathing patterns of two girls with Rett syndrome. J Intellect Disabil Res. 1996;40:252–259. [PubMed]
117. Xinhua B, Shengling J, Fuying S, Hong P, Meirong L, Wu XR. X chromosome inactivation in Rett syndrome and its correlations with MECP2 mutations and phenotype. J Child Neurol. 2008;23:22–25. [PubMed]
118. Yasui DH, Peddada S, Bieda MC, Vallero RO, Hogart A, Nagarajan RP, Thatcher KN, Farnham PJ, Lasalle JM. Integrated epigenomic analyses of neuronal MeCP2 reveal a role for long-range interaction with active genes. Proc Natl Acad Sci USA. 2007;104:19416–19421. [PubMed]
119. Young JI, Hong EP, Castle JC, Crespo-Barreto J, Bowman AB, Rose MF, Kang D, Richman R, Johnson JM, Berget S, Zoghbi HY. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc Natl Acad Sci USA. 2005;102:17551–17558. [PubMed]
120. Zanella S, Mebarek S, Lajard AM, Picard N, Dutschmann M, Hilaire G. Oral treatment with desipramine improves breathing and life span in Rett syndrome mouse model. Respir Physiol Neurobiol. 2008;160:116–121. [PubMed]
121. Zhang L, He J, Jugloff DG, Eubanks JH. The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability. Hippocampus. 2008;18:294–309. [PubMed]
122. Zoghbi HY, Percy AK, Glaze DG, Butler IJ, Riccardi VM. Reduction of biogenic amine levels in the Rett syndrome. N Engl J Med. 1985;313:921–924. [PubMed]
123. Zoghbi HY, Milstien S, Butler IJ, Smith EO, Kaufman S, Glaze DG, Percy AK. Cerebrospinal fluid biogenic amines and biopterin in Rett syndrome. Ann Neurol. 1989;25:56–60. [PubMed]